Binding agents and methods of using the same
AssigneeMozart Therapeutics, Inc
InventorsCourtney Crane, Kristine Swiderek, Susan Julien
Life of this patent
Estimating the term…
Abstract
The present invention provides binding agents that specifically bind to CD8+KIR+ T regulatory cells and their use in the treatment of diseases or disorders, such as an inflammatory disease, an autoimmune disease, cancer, or an infectious disease.
Claims11
A binding agent comprising:
- a first binding domain that specifically binds to CD8 or a subunit of CD8 and comprises a heavy chain variable region (VH) comprising an hCDR1, an hCDR2, and an hCDR3 and a light chain variable region (VL) comprising an ICDR1, an ICDR2, and an ICDR3, wherein the hCDR1, hCDR2, hCDR3, ICDR1, ICDR2, and ICDR3 have amino acid sequences of SEQ ID NO:83 to SEQ ID NO:88, respectively;
- a second binding domain that specifically binds to an inhibitory KIR protein expressed on CD8+KIR+ T regulatory cells (Tregs);
- and
- an IgG Fc domain.
A method of reducing the number or activity of autoreactive CD4+ T cells present in a subject in need thereof, comprising administering a binding agent to the subject in an amount effective to decrease the number or activity of autoreactive CD4+ T cells, wherein the binding agent binds to CD8+KIR+ regulatory T cells (Tregs) and comprises:
- a first binding domain that specifically binds to CD8 or a subunit of CD8 and comprises a heavy chain variable region (VH) comprising an hCDR1, an hCDR2, and an hCDR3 and a light chain variable region (VL) comprising an ICDR1, an ICDR2, and an ICDR3, wherein the hCDR1, hCDR2, hCDR3, ICDR1, ICDR2, and ICDR3 have amino acid sequences of SEQ ID NO:83 to SEQ ID NO:88, respectively;
- and
- a second binding domain that specifically binds to an inhibitory KIR protein expressed on CD8+KIR+ T regulatory cells (Tregs);
- and
- an IgG Fc domain.
Dependencies are inferred from the claim text.